| Date Filed | Type | Description |
| 10/05/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/15/2023 |
3
| Dais Craig (CFO) has filed a Form 3 on NAVIDEA BIOPHARMACEUTICALS, INC. |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Resignation/termination of a director |
| 07/28/2023 |
8-K
| Quarterly results |
| 07/17/2023 |
4
| Moss Dana J (Director) has filed a Form 4 on NAVIDEA BIOPHARMACEUTICALS, INC.|
Txns:
| Granted 250,000 shares
@ $0 |
|
| 07/17/2023 |
3
| Moss Dana J (Director) has filed a Form 3 on NAVIDEA BIOPHARMACEUTICALS, INC. |
| 07/13/2023 |
8-K
| Resignation/termination of a director |
| 07/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
| 07/03/2023 |
SC 13D/A
| Scott John K Jr. reports a 75% stake in Navidea Biopharmaceuticals, Inc. |
| 07/03/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/03/2023 |
SC 13G/A
| Bain Irwin Allen reports a 4.7% stake in Navidea Biopharmaceuticals, Inc. |
| 06/30/2023 |
SC 13G/A
| Bain Irwin Allen reports a 4.7% stake in Navidea Biopharmaceuticals, Inc. |
| 06/30/2023 |
4
| Scott John K Jr. (10% Owner) has filed a Form 4 on NAVIDEA BIOPHARMACEUTICALS, INC.|
Txns:
| Granted 12,200,000 shares
@ $0.088, valued at
$1.1M
|
|
| 06/16/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 06/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 06/16/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 06/16/2023 |
8-A12G
| Form 8-A12G - Registration of securities [Section 12(g)]: |
| 06/16/2023 |
SC 13D/A
| Scott John K Jr. reports a 52.8% stake in Navidea Biopharmaceuticals, Inc. |
| 06/15/2023 |
4
| Scott John K Jr. (10% Owner) has filed a Form 4 on NAVIDEA BIOPHARMACEUTICALS, INC.|
Txns:
| Disposed of 990 shares
@ $0
Granted 11,508,672 shares
@ $0
Bought 11,969 options to buy
@ $0.104, valued at
$1.2k
Converted 11,969 options to buy
@ $0.104, valued at
$1.2k
|
|
| 06/12/2023 |
4
| Stefanelli Jill (Director) has filed a Form 4 on NAVIDEA BIOPHARMACEUTICALS, INC.|
Txns:
| Granted 250,000 shares
@ $0 |
|
| 06/09/2023 |
3
| Stefanelli Jill (Director) has filed a Form 3 on NAVIDEA BIOPHARMACEUTICALS, INC. |
| 05/25/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ... |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Opinion of Maslon LLP",
"Common Stock Purchase Agreement between Navidea Biopharmaceuticals, Inc. and Keystone Capital Partners, LLC",
"Registration Rights Agreement between Navidea Biopharmaceuticals, Inc. and Keystone Capital Partners, LLC",
"Secured Bridge Note",
"First Amendment to Security Agreement between Navidea Biopharmaceuticals, Inc. and John Kim Scott, Jr",
"[email protected]" |
|
| 04/28/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/13/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/10/2023 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Financial Statements and Ex... |
| 12/22/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 12/12/2022 |
8-K
| Quarterly results |
| 11/30/2022 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
|